Leukemia 2014 Sep 19

Allogeneic and Autologous Stem Cell Transplantation for hepatosplenic T cell lymphoma: A retrospective study of the EBMT Lymphoma Working party.

Tanase A1, Schmitz N2, Stein H3, Boumendil A4, Finel H4, Castagna L5, Blaise D6, Milpied N7, Sucak G8, Sureda A9, Thomson K10, Vandenberghe E11, Vitek A12, Dreger P13.
The objective of this registry study was to analyze the outcome of patients who underwent allogeneic or autologous hematopoietic stem cell transplantation (HSCT) for hepatosplenic T cell lymphoma (HSTL), a rare and extremely aggressive peripheral T cell lymphoma subtype. Patients were eligible if they had histologically verified HSTL and underwent HSCT between 2003 and 2011. 76 patients were identified in the EBMT database. Additional baseline and follow-up information could be obtained from the referring centres for 36 patients. Eleven of these were excluded following histopathology review, leaving 25 patients in the final study cohort (alloHSCT 18, autoHSCT 7). With a median follow-up of 36 months, 2 patients relapsed after alloHSCT, resulting in a 3-year progression-free survival of 48%. After autoHSCT, 5 patients relapsed and subsequently died. This study indicates that graft-versus-lymphoma activity conferred by alloHSCT can result in long-term survival for a substantial proportion of patients with HSTL.Leukemia accepted article preview online, 19 September 2014. doi:10.1038/leu.2014.280.
his registry study was to analyze the outcome of patients who underwent allogeneic or autologous hematopoietic stem cell transplantation (HSCT) for hepatosplenic T cell lymphoma (HSTL), a rare and extremely aggressive peripheral T cell lymphoma subtype. Patients were eligible if they had histologically verified HSTL and underwent HSCT between 2003 and 2011. 76 patients were identified in the EBMT database. Additional baseline and follow-up information could be obtained from the referring centres for 36 patients. Eleven of these were excluded following histopathology review, leaving 25 patients in the final study cohort (alloHSCT 18, autoHSCT 7). With a median follow-up of 36 months, 2 patients relapsed after alloHSCT, resulting in a 3-year progression-free survival of 48%. After autoHSCT, 5 patients relapsed and subsequently died. This study indicates that graft-versus-lymphoma activity conferred by alloHSCT can result in long-term survival for a substantial proportion of patients with HSTL.Leukemia accepted article preview online, 19 September 2014. doi:10.1038/leu.2014.280.